During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
|Videos|August 19, 2014
The Goal of the SystHERs Registry
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.
Advertisement
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.
Clinical Pearls:
- This registry will enroll patients who have been diagnosed with HER2/neu-positive metastatic breast cancer within the last 6 months.
- The registry will collect detailed information on patients who are diagnosed with HER2 metastatic breast cancer to look both at the demographic factors as well as their past history.
- The registry will also look at what treatment they receive in the metastatic setting, what their outcomes are in terms of response and side effects.
- This will help researchers better understand how patients react to new agents that have been developed in this space.
Advertisement
Related to this article
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5